CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05188495
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:20.849797+00:00
Published At: 2022-01-12T00:00:00+00:00
Record Updated At: 2022-01-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["HER2-positive Metastatic Breast Cancer", "Previously Treated With Trastuzumab", "Trastuzumab Combined With Pertuzumab and Chemotherapy"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-01-12"
protocolSection.identificationModule.nctId: "NCT05188495"
protocolSection.identificationModule.officialTitle: "Phase II Study of Trastuzumab(Henlius\u00ae) Combined With Pertuzumab(Perjeta\u00ae) and Chemotherapy in Chinese Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.